Complications of allogeneic hematopoietic stem cell transplantation

Cancer Investigation

Volumn 32, Issue 7, 2014, Pages 349-362

  Arnaout, Karim ^a   Patel, Nihar ^a   Jain, Maneesh ^a   El Amm, Joelle ^a   Amro, Farah ^a   Tabbara, Imad A ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplant; Leukemias; Long term survival and late effects

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELLULAR IMMUNODEFICIENCY; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS INFECTION; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; SINUSOIDAL OBSTRUCTIVE SYNDROME; VEIN OCCLUSION;

BONE MARROW TRANSPLANT; LEUKEMIAS; LONG-TERM SURVIVAL AND LATE EFFECTS;

BACTERIAL INFECTIONS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MYCOSES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS DISEASES; WHOLE-BODY IRRADIATION;

EID: 84903991227     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.919301     Document Type: Article

References (157)

1. Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011;1(4):e (16). Retrieved October 12, 2012, from http://www.ncbi.nlm.nih.gov/ pmc/ articles/PMC3255242/pdf/bcj201114a.pdf.
2. Gyurkocza B, Revzani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert RevHematol 2011;3(3): 285-299.
3. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM. Graft-versus-leukemia reactions after bonemarrow transplantation. Blood 1990;75(3): 555-562.
4. Pecatori J, Ciceri F. Allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010;95(6): 857-859.
5. Gupta V, Lazarus HM, Keating A. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant 2003;32(10): 969-978. (Pubitemid 37461532)
6. Bredeson C, Le Rademacher J, Kato K, Di Persio JF, Agura E, Devine SM, Applebaum FR, Tomblyn MR, Laport GG, Zhu X, Mc Carthy PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM, Pasquini MC. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 2013;122(24): 3871-3878.
7. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI. Blood 2013;122(24): 3863-3870.
8. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010;3(36).
9. Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Gibson LF, Remick SC, Leadmon S, Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson Jr. DM, Devine SM. Higher busulfan dose intensity does not improve outcomes of patients undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT) Following Fludarabine/Busulfan/Atg (FBA)- Based Reduced Toxicity Conditioning (RTC). Biol Blood Marrow Transplant 2011;17(2):S306.
10. Jillella AP, Doria R, Khan K, Zelterman D, Ahmad YH, Smith BR, Holmes W, Becker P, Roberts KB, Rappeport JM. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplant 1999;23(11): 1095-1100. (Pubitemid 29259664)
11. Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ, Sanders JE, Storb R. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combinedwith antithymocyte globulin. Br J Haematol 2005;130(5): 747-751. (Pubitemid 43906647)
12. Uberti JP, Agovi MA, Tarima S, Haagenson M, Gandham S, Anasetti C, Baker KS, Bolwell BJ, Bornhauser M, Chan KW, Copelan E, Davies SM, Finke J, Hale GA, Kollman C, Mc Carthy PL, Ratanatharathorn V, Ringdén O, Weisdorf DJ, Rizzo JD. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant 2011;46: 34-43. Retrieved October 20, 2012, from http://www.nature.com/bmt/journal/v46/n1/pdf/bmt201081a.pdf
13. Belkacémi Y, Labopin M, Hennequin C, Hoffstetter S, Mungai R, Wygoda M, Lundell M, Finke J, Aktinson C, Lorchel F, Durdux C, Basara N. Reduced intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. Int J Rad Oncol, Biol, Phys 2007;67(2): 544-551. (Pubitemid 46108301)
14. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006;20(2): 322-328. (Pubitemid 43148672)
15. Sayer HG, Kröger M, Beyer J, Kiehl M, Klein SA, Schaefer- Eckart K, Schwerdtfeger R, Siegert W, Runde V, Theuser C, Martin H, Schetelig J, Beelen DW, Fauser A, Kienast J, Höffken K, Ehninger G, Bornhäuser M; Cooperative German Transplant Study Group. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia:disease status bymarrowblasts is the strongest prognostic factor. Bone Marrow Transplant 2003;31(12): 1089-1095. (Pubitemid 36857366)
16. Kohrt H, Lowsky R. Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. Curr Opin Hematol 2009;16(6): 460-465. Retrieved October 26, 2012, from http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2925420/pdf/nihms224948.pdf
17. Tabbara IA, Ingram RM. Nonmyeloablative therapy and allogeneic transplantation. Exp Hematol 2003;31(7): 559-66.
18. Pollack SM, O'Connor TP Jr, Hashash J, Tabbara IA. Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem Cell Transplantation: A Clinical Review. Am J Clin Oncol 2009;32(6): 618-628.
19. Lenarsky, C. Immune recovery after bone marrow transplantation. Curr Opin Hematol 1995;2(6): 409-412.
20. Koehl C, Bochenneck K, Zimmermann SY. Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+CD3+ count reconstitution is associated with survival. Bone Marrow Transplant 2007;39: 269-278. (Pubitemid 46322633)
21. Shepp DH, Meyers JD. Viral Infections in the compromised host. In: Current therapy in hematology-oncology, 1985-1986, MC Brian, P Carbone, (eds.). Philadelphia, Pa: BC Decker Inc, 1985, 102-108.
22. Zaia JA. Viral infections associated with bone marrow transplantation. Hematol Oncol Clin North Am 1990;4(3): 603-23. (Pubitemid 20174580)
23. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes simplex virus infections: a randomized, double-blind controlled trial in bone marrow transplant recipients. N Engl J Med 1981;305: 63-67. (Pubitemid 12247924)
24. Feinstein MB, Mokhtari M, Ferreiro R, Stover DE, Jakubowski A. Fiberoptic bronchoscopy in allogeneic bone marrow transplantation: findings in the era of serum cytomegalovirus antigen surveillance. Chest 2001;120(4): 1094-1100. (Pubitemid 32960077)
25. Leung AN, Gosselin MV, Napper CH, Braun SG, Hu WW, Wong RM, Gasman J. Pulmonary infections after bone marrow transplantation: clinical and radiographic findings. Radiology 1999;210: 699-710. (Pubitemid 29124030)
26. Patel NR, Lee P, Kim JH, Weinhouse GL, Koziel H. The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients. Chest 2005;127(4): 1388-1396. (Pubitemid 46224306)
27. Atkinson K, Nivison-Smith I, Dodds A, Concannon A, Miliken S, Downs K. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989. Bone Marrow Transplant 1998;21(7): 691-695. (Pubitemid 28159606)
28. Ibrahim A, Gautier E, Roittmann S, Bourhis JH, Fajac A, Charnoz I, Terrier P, Salord J-M, Tancrède C, Hayat M, Bernaudin J-F, Pico J-L. Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bonemarrow transplantation? Br J Haematol 1997;98(1): 222-227. (Pubitemid 27348821)
29. Sakuma H, Hosoya M, Kanno H, Kikuta A, Konno K, Kawano Y, Takaue Y, Shigeta S, Suzuki H. Risk of cytomegalovirus infection after peripheral blood stem cell transplantation. Bone Marrow Transplant 1997;19(1): 19-53.
30. Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, Iida H, Shimokawa T, Kohno A, Mizuta S, Maruyama F, Wakita A, Kitaori K, Yano K, Hamaguchi M, Hamajima N, Morishima Y, Kodera Y, Sao H, Morishita Y. Cytomegalovirus antigenemia and outcome of patients treated with preemptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;32(8): 801-807. (Pubitemid 38455945)
31. Enright H, Haake R, Weisdorf D, Ramsay N, McGlave P, Kersey J, Thomas W, McKenzie D, Miller W. Cytomegalovirus pneumonia after bone marrow transplantation: risk factors and response to therapy. Transplantation 1993;55(6): 1339-1346. (Pubitemid 23183248)
32. Zekri AR, Mohamed WS, Samra MA, Sherif GM, El-Shehaby AM, El-Sayed MH. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transplant Immunol 2004;13(4): 305-311. (Pubitemid 39602598)
33. Kim DH, Kim JG, Lee NY, Sung WJ, Sohn SK, Suh JS, Lee KS, Lee KB. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection. Bone Marrow Transplant 2004;34(1): 21-27. (Pubitemid 39022953)
34. Morfin F, Boucher A, Najioullah F, Bertrand Y, Bleyzak N, Poitevin-Later F, Bienvenu F, Simonet V, Galambrun C, Philippe N, Aymard M, Thouvenot D, Souillet G. Allogeneic stem cell transplantation for acute myeloid leukemia. J Med Virol 2004;72(2): 257-262.
35. Yoo JH, Lee DG, Choi SM, Choi JH, Park YH, Kim YJ, Kim Y, Kim HJ, Lee S, Kim DW, Lee JW, Min WS, Shin WS, Kim CC. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 2004;34(6): 497-504. (Pubitemid 39264039)
36. Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, Nguyen Q, Whimbey E. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001;27(8): 877-881. (Pubitemid 32496423)
37. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirusseronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78(1): 246-250.
38. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE. Intravenous immunoglobulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987;106(1): 12-18. (Pubitemid 17015185)
39. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Champlin RE. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314(16): 1006-1010. (Pubitemid 16138695)
40. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118(3): 173-178. (Pubitemid 23034801)
41. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, doubleblind trial. Ann Intern Med 1993;118(3): 179-184. (Pubitemid 23034802)
42. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia, JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991;324(15): 1005-1011.
43. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992;166(3): 473-479.
44. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, Corey L. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004;42(3): 1142-1148. (Pubitemid 38332838)
45. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell hen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, Wagner JL, Witherspoon RP, Anasetti C, Appelbaum FR, Bensinger WI, Deeg HJ, Martin PJ, Sanders JE, Storb R, Storek J, Wade J, Siadak M, Flowers ME, Sullivan KM. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow transplantation. N Engl J Med 2013;369(13): 1227-1236.
46. Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, Wagner JL, Witherspoon RP, Anasetti C, Appelbaum FR, Bensinger WI, Deeg HJ, Martin PJ, Sanders JE, Storb R, Storek J, Wade J, Siadak M, Flowers ME, Sullivan KM. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;32(5): 515-522. (Pubitemid 37160968)
47. Goodman JL, Winston DJ, Greenfield RA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326(13):845-851
48. Slavin MA, Osborne B, Adams R. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995;171(6):1545-1552
49. Ullmann AJ, Lipton JF, Vesole DH. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease. N Engl J Med 2007;356(4):335-347 (Pubitemid 46148776)
50. Marr KA, Bowden RA. Fungal infections in patients undergoing blood and marrow transplantation. Transpl Infect Dis 1999;1(4): 237-246.
51. Soubani AO, Qureshi MA. Invasive pulmonary aspergillosis following bone marrow transplantation: risk factors and diagnostic aspect. Haematologia 2002;32(4): 427-437. (Pubitemid 36665352)
52. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002;121(6): 1988-1999. (Pubitemid 34634424)
53. Horger M, Einsele H, Schumacher U, Wehrmann M, Hebart H, Lengerke C, Vonthein R, Claussen CD, Pfannenbecrg C. Invasive pulmonary aspergillosis: frequency and meaning of the 'hypodense sign' on unenhanced CT. Br J Radiol 2005;78(932): 697-703. (Pubitemid 41122682)
54. Bialek R, Moshous D, Casanova JL, Blanche S, Hennequin C. Aspergillus antigen and PCR assays in bone marrow transplanted children. Eur J Med Res 2002;7(4): 177-80.
55. Herbrecht R, Denning DW, Patterson TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6): 408-415. (Pubitemid 34851833)
56. Kontoyiannis DP, Wessel VC, Bodey JP. Zygomycosis in the 1990s in a Tertiary-Care Cancer Center. Clin Infect Dis 2000;30(6): 135-1360.
57. Roden MM, Zaoutis TE, Buchanan WL. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41(5): 634-653. (Pubitemid 41170352)
58. Centers for Disease Control and Prevention. Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. Morb Mortal Wkly Rep 2000;49: 1-128. Retrieved October 29, 2012, from http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm
59. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies Bone marrow transplantation. Bone Marrow Transplant 2008;41: 229-237 (Pubitemid 351260376)
60. Barrett AJ, Savani BN. Stem cell transplantation with reducedintensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006;20(10): 1661-1672. (Pubitemid 44574980)
61. Carreras E, Diaz-Beya M, Rosinol L, Martinez C, Fernandez- Aviles F, Rovira M. The incidence of venoocclusive disease following allogeneic hematopoietic stemcell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011;17(11): 1713-1720.
62. Carreras E, Bertz H, Arcese W, Vernant JP, Tomás JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European group for blood and marrow transplantation. Blood 1998;92(10): 3599-3604. (Pubitemid 28525185)
63. Tabbara IA, Ghazal CD, Ghazal HH. Early drop in protein C and antithrombin III levels is a predictor for the development of venoocclusive disease in patients undergoing bone marrow transplantation. J Hematother 1996;5(1): 79-84.
64. Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997;89(6): 2184-2188. (Pubitemid 27132137)
65. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, Mc Donald GB. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11(9): 1729-1736. (Pubitemid 23277325)
66. Bearman SI, Lee JL, Baron AE, Mc Donald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42marrow transplant patients. Blood 1997;89: 1501-1506. (Pubitemid 27097440)
67. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice H.G, Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000;111(4): 1122-1129. (Pubitemid 32104928)
68. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100(13): 4337-4343. (Pubitemid 35429671)
69. Richardson PG, Smith AR, Grupp SA, Kernan NA, Arai S, Haut PR, Triplett BM, Gillio AP, III, Symons HJ, Adams RH, Horn BN, Lucas K, Martin PL, Mineishi S, Ball ED, Boyer M, Fort J, Kirov II, Lehmann LE, Madigan C, Maglio ME, Massaro J, D'Agostino RB, Hannah AL, Tudone E, Hume R, Iacobelli M, Soiffer RJ, and Defibrotide Study Group. Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. Blood 2011 (ASHAnnualMeeting Abstracts):118:487.
70. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe venoocclusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92(3): 737-744. (Pubitemid 28355454)
71. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shields A, Singer JW. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991;78(5): 1205-1211.
72. Kalhs P, Lechner K, Stockschlader M, Kruger W, Peters S, Zander A. Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients. Blood 1992;80(10): 2683-2684.
73. Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, Bakke L, Bensinger WI, Bowden RA, McDonald GB, Schubert M. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993;82(7): 2025-2030. (Pubitemid 23293983)
74. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, Voigt JJ, Brousset P, Selves J, Muller C, Pris J, Laurent J. Prevention of hepatic veno occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992;79(11): 2834-2840.
75. Essell JH, Thompson JM, Harman GS, Halvorson RD, Synder MJ, Callander NS, Clement DJ. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1992;10(4): 367-372.
76. Dignan F, Gujral D, Ethell M, Evans S, Treleaven J, Morgan G, Potter M. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from venoocclusive disease. Bone Marrow Transplant 2007;40(1): 79-82. (Pubitemid 47018417)
77. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graftversus- host disease in human recipients of marrow from HL-Amatched sibling donors. Transplantation 1974;18(4): 295-304.
78. Billingham RE.The biology of graft-versus-host reactions. Harvey Lect 1966-1967;62: 21-78.
79. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol BloodMarrow Transplant 2005;11(12): 945-956. (Pubitemid 41754712)
80. Goulmy E, Schipper R, Pool J, Blockland E, Falkenburg JH, Vossen J, Gratwohl A, Vogelsang GB, van Houwelingen HC, van Rood JJ. Mismatches of minor histocompatibility antigens betweenHLA- identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334(5): 281-285. (Pubitemid 26033083)
81. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110(13): 4576-4583. (Pubitemid 351377826)
82. Loiseau P, Busson M, Balere M, Dormoy A, Bignon J, Gagne K, Gebuhrer L, Dubois V, Jollet I, Bois M, Perrier P, Masson D, Moine A, Absi L, Reviron D, Lepage V, Tamouza R, Toubert A, Marry E, Chir Z, Jouet JP, Blaise D, Charron D, Raffoux C.HLA Association with Hematopoietic Stem Cell Transplantation Outcome: The Number of Mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 Is Strongly Associated with Overall Survival. Biol Blood and Marrow Transplant 2007;13: 965-974. (Pubitemid 47055388)
83. Center for International Blood & Marrow Transplant Research. Progress Report (January-December 2008). Retrieved October 6, 2012, from http://www.cibmtr.org/About/ ProceduresProgress/Documents/2008 CIBMTR Annual R.pdf
84. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden RA, Deeg HJ, Doney K. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992;80: 1838-1845.
85. Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz R, van Rood J, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringdén O. Risk factors for acute graft-versus-host disease after human leukocyte antigenidentical sibling transplants for adults with leukemia. J Clin Oncol 2008;26(35): 5728-5734.
86. Gale RP, Bortin MM, van bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffmann RG, Kay HE, Kersey JH. Risk factors for acute graft-versus-host disease. Br J Haematol 1987;67(4): 397-406. (Pubitemid 18032036)
87. Kim DD, Yun J, Won HH, Cheng L, Su J, Xu W, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH. Multiple singlenucleotide polymorphism based riskmodel for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease. Transplantation 2012;94(12): 1250-1257.
88. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119(1): 296-307.
89. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt M, Reddy P, ChinA, ZhangQ, Hanash S, Paczesny S. Regenerating islet derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011;118(25): 6702-6708.
90. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrera JL, Ho VT, Weisdorf D J, Paczesny S. Acute graft-versus host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012;119(16): 3854-3860.
91. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socié G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM. IBMTR severity index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol 1997;97: 855-864. (Pubitemid 27321388)
92. Hu SW, Cotliar J. Acute graft-versus-host disease following hematopoietic stem-cell transplantation. Dermatologic Therapy 2011;24(4): 411-423.
93. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs. host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc 1974;6(4): 367-371.
94. Weisdorf DJ, Snover DC, Haake R. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990;76(3): 624-629. (Pubitemid 20251834)
95. WakuiM, Okamoto S, Ishida A, Kobayashi H. Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. BoneMarrow Transplant 1999;23(6): 573-578. (Pubitemid 29137446)
96. Sale GE, Lerner KG, Barker EA, Shulman HM, Thomas ED.The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 1977;89(3): 621-635. (Pubitemid 8254190)
97. Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graftversus- host disease. Am J Surg Pathol 1997;21(9): 988-996. (Pubitemid 27407282)
98. Kuykendall TD, Smoller BR. Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3weeks after bone-marrowtransplantation. JAmAcadDermatol 2003;49(6): 1081-1085. (Pubitemid 37475481)
99. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine JE, Hanash SM, Ferrara JL. A biomarker panel for acute graft-versus-host disease. Blood 2009;113(2): 273-278.
100. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314(12): 729-735. (Pubitemid 16124386)
101. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versushost disease. N Engl J Med 1993;329: 1225-1230. (Pubitemid 23306323)
102. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009;43(8): 643-653.
103. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard Jr. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92(7): 2303-2314. (Pubitemid 28452971)
104. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V. Phase 3 study comparingmethotrexate and tacrolimus withmethotrexate and cyclosporine for prophylaxis of acute graft-versus host disease after marrow transplantation from unrelated donors. Blood 2000;96: 2062-2068.
105. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004;34(7): 621-625. (Pubitemid 39341543)
106. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, Van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Goodet RA. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78(8): 2120-2130.
107. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10(9): 855-864.
108. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ. Sirolimus, tacrolimus, and low dose methotrexate for graft-versus-host disease prophylaxis inmismatched related donor or unrelated donor transplantation. Blood 2003;102(5): 1601-1605. (Pubitemid 37022548)
109. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood
110. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Phil D, Porter DL. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012;367: 135-145.
111. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010;47(1-3): 65-77.
112. Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ.High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115(16): 3224-3230.
113. Penas PF, Fernandez-Herrera J, Garcia-Diez A. Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol 2004;5(6): 403-416. (Pubitemid 40175258)
114. Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von Bergwelt-Baildon M, Held SA, Brossart P. Novel treatment concepts for graft-versus-host disease. Blood 2012;119(1): 16-25.
115. Linhares YP, Pavletic S, Gale RP. Chronic GVHD: where are we? Where do we want to be?Will immunomodulatory drugs help? Bone Marrow Transplant 2013;48(2): 203-209.
116. Lee SJ, Flowers ME. Recognizing and managing chronic graftversus- host disease. Hematol/ Am Soc Hematol, Education Program 2008;134-141.
117. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, Pereira SE, Nash RA, Mielcarek M, Fero ML, Warren EH, Sanders JE, Storb RF, Appelbaum FR, Storer BE, Martin PJ. Comparative analysis of risk factors for acute graft-versushost disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117(11): 3214-3219.
118. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer SL. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367(16): 1487-1496.
119. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 2004;79(3): 209-215. (Pubitemid 38620767)
120. Penas PF, Zaman S.Many faces of graft-versus-host disease. Aust J Dermatol 2010;51(1): 1-10.
121. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001;97(5): 1196-1201. (Pubitemid 32183739)
122. Kottaridis PD, Milligan DW, Chopra R. In vivo CAMPATH-1H preventsGvHDfollowing nonmyeloablative stem-cell transplantation. Cytotherapy 2001;3(3): 197-201. (Pubitemid 33039657)
123. Hale G, Zhang MJ, Bunjes D. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92: 4581-4590. (Pubitemid 29005860)
124. Barge RM, Starrenburg CW, Falkenburg JH. Long-term followup of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transplant 2006;37(12): 1129-1134. (Pubitemid 43871523)
125. Luznik L, Bolanos-Meade J, Zahurak M. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graftversus- host diseaseHigh-dose Cyclophosphamide as singleagent, short course prophylaxis of graft-versus-host disease. Blood 2010;115(16):3224-3230
126. Soiffer RJ, Weller E, Alyea EP. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.AmJ Pathol 2001;19(4): 1152-1159.High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseasHigh-dose cyclophosphamide as singleagent, short-course prophylaxis of graft-versus-host disease. (Pubitemid 32176293)
127. Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Shaw BE, Potter MN. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012;158(1): 46-61.
128. Farag SS.Chronic graft-versus-host disease:where dowe go from here? Bone Marrow Transplant 2004;33(6): 569-577. (Pubitemid 38455918)
129. Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002;29(7): 545-552. (Pubitemid 34537712)
130. Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S, Vierra-Green C, Anasetti C. The detection of donordirected, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010;115(13): 2704-2708.
131. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA, Rozman C. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989;73(2): 606-613. (Pubitemid 19060551)
132. Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, Buzyn A, Lioure B, Bordigoni P, Fegueux N, Tanguy ML, Vernant JP, Gluckman E, Socié G. Second early allogeneic stemcell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French society of bone marrow transplantation. Br J Haematol 2000;111(1): 292-302.
133. Grandage VL, Cornish JM, Pamphilon DH, Potter MN, Steward CG, Oakhill A, Marks DI. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bonemarrow transplantation. Bone Marrow Transplant 1998;21(7): 687-690. (Pubitemid 28159605)
134. Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T; MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic stem cell transplantation formyelodysplatic syndromes with bone marrow fibrosis. Haematologica 2011;96 (2): 291-297.
135. Hubel K, Weingart O, Naumann F, Bohlius J, Fresen MM, Engert A, Wheatley K. Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systemic analysis of international guidelines and recommendations. Leuk Lymphoma 2011;52 (3): 444-457.
136. Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, Min CK, Lee JW, Min WS, Kim CC.The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2009;115 (3): 561-570.
137. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994;84: 3603-3612. (Pubitemid 24362455)
138. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA, Sanders JE, Storb R, Thomas ED. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989;7(1): 50-57. (Pubitemid 19089081)
139. Elmaagacli AH, Beelen DW, Trenn G, Schmidt O, Nahler M, Schaefer UW. Induction of a graft-versus-leukemia reaction by cyclosporine A withdrawal as immunotherapy for leukemia relapsing after allogeneic bonemarrow transplantation. Bone Marrow Transplant 1999;23 (8): 771-777. (Pubitemid 29186886)
140. Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E, Alessandrino PE, Locatelli F, Vernant JP, Sierra J, Jouet JP, Frassoni F; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Second allogeneic bone marrow transplantation inacute leukemia: resultsof a surveyby theEuropean Cooperative Group for Blood andMarrow Transplantation. J Clin Oncol 2001;19(16): 3675-3684. (Pubitemid 32786280)
141. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringdén O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, de- Lima M. Second transplant for acute and chronic leukemia relapsing after firstHLA-identical sibling transplant. Bone Marrow Transplant 2004;34(8): 721-727. (Pubitemid 39406056)
142. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, Collins RH. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002;20(2): 405-412. (Pubitemid 34072522)
143. Choi SJ, Lee JH, Kim S, Seol M, Lee YS, Lee JS, Kim WK, Chi HS, Lee KH. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004;18(11): 1789-1797. (Pubitemid 39530008)
144. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin N-C, Kolb H-J, Rocha V. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007;25(31): 4938-4945. (Pubitemid 350225492)
145. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009;115(9): 1899-1905.
146. Martino M, Fedele R, Moscato T, Ronco F.Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents. Current Cancer Drug Targets 2013;13(6): 661-669.
147. Im A, Raptis A, Hou JZ, Tompkins C, Loucks M, Guay M, Phillips J, Boyiadzis M, Agha M. Hypomethylating agents for relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Biology of Blood and Marrow Transplant 2013;19(2):S293.
148. Kolb HJ, Socié G, Duell T, Van Lint MT, Tichelli A, Apperley JF, Nekolla E, Ljungman P, Jacobsen N, vanWeel M, Wick R, Weiss M, Prentice HG.Malignant neoplasms in long-term survivors of bone marrow transplantation. Late effects working party of the European cooperative group for blood and marrow transplantation and the European late effect project group. Ann Intern Med 1999;131(10): 738-744.
149. Heilmeier B, Stowasser N, Socie G, van Lint MT, Tichelli A, Salooja N, Nekolla E, Ljungman PT, Jacobsen N, vanWeel M, Tischer J, Ledderose G, Fliedner TM, and Kolb HJ. Malignant neoplasms in long-term survivors of bone marrow transplantation - follow up. Blood 2008;112:453.
150. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009;113(5): 1175-1183.
151. Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, Bolwell B, Wingard JR, Socie G. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011;117(1): 316-322.
152. Friedman DL, Rovo A, Leisenring W, Locasciulli A, Flowers ME, Tichelli A, Sanders JE, Deeg HJ, Socie G; FHCRC; EBMTLate Effect Working Party. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report fromthe FHCRCand the EBMT-Late Effect Working Party. Blood 2008;111(2): 939-944.
153. Sanders JE. Impact of marrow transplantation on subsequent fertility. In Hematologic disorders in maternal-fetal medicine, MM Bern, FD Frigoletto (eds.) New York, NY: Wiley-Liss Inc., 1990;327-334.
154. Belkacemi Y, Labopin M, Vernant JP, Prentice HG, Tichelli A, Schattenberg A, Boogaerts MA, Ernst P, Della Volpe A, Goldstone AH, Jouet JP, Verdonck LF, Locasciulli A, Rio B, Ozsahin M, Gorin NC. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood andMarrow Transplantation. Int J Rad Oncol, Biol, Phys 1998;41(3): 659-668. (Pubitemid 28275099)
155. Au WY, Ho JC, Lie AK, Sun J, Zheng L, Liang R, Lam WK, Tsang KW. Respiratory ciliary function in bone marrow recipients. Bone Marrow Transplant 2001;27(11): 1147-1151. (Pubitemid 32600287)
156. Locasciulli A, Alberti A, De Bock R, Cordonnier C, Einsele H, Engelhard D, Grundy J, Reusser P, Ribaud P, Ljungman P. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group-Infectious Diseases Working Party. Bone Marrow Transplant 1994;14(5): 833-837.
157. Mc Kay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P, Franklin IM. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996;17(1): 63-66. (Pubitemid 26031892)